TGFß INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT

• US 20190330291A1
• Filed: 06/19/2017
• Published: 10/31/2019
• Est. Priority Date: 06/17/2016
• Status: Abandoned Application

• Current Assignee: Momotaro-Gene Inc.
• Original Assignee: Momataro-Gene Incorporated
• Inventors: KINOSHITA, Rie, FUTAMI, Junichiro, KUMON, Hiromi
• Application Number:
  US16/310,188
• Publication Number:
  US 20190330291A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors

Abstract

For purposes of providing a pharmaceutical to be used for preventing or treating a TGFβ-related disease by inhibiting signaling of TGFβ, the present invention provides a TGFβ inhibitor comprising, as an active ingredient, REIC/Dkk-3 protein or a partial protein thereof comprising a Cys-rich domain thereof, or a DNA encoding any of these proteins, and an agent for preventing or treating a TGFβ-related disease containing the TGFβ inhibitor.

Claims

1. A TGFβ

inhibitor, comprising, as an active ingredient, REIC/Dkk-3 protein or a partial protein thereof comprising a Cys-rich domain thereof, or a DNA encoding any of the proteins.

2. The TGFβ

inhibitor according to claim 1, comprising the REIC/Dkk-3 protein or the partial protein thereof comprising the Cys-rich domain thereof, the TGFβ

inhibitor inhibiting a reaction between TGFβ and

a receptor of the TGFβ

concentration-dependently in a concentration region corresponding to an active dose of 50 nM or more.

3. The TGFβ

inhibitor according to claim 1, the TGF inhibitor not completely inhibiting a reaction between TGFβ and

a receptor of the TGFβ

even when an active dose is high.

4. The TGFβ

inhibitor according to claim 3, wherein the TGFβ

inhibitor does not completely inhibit the reaction between the TGFβ and

the receptor even when the active dose is 375 nM or more.

5. An anti-tumor immune activating agent, comprising the TGFβ

inhibitor according to claim 1.

6. An agent for preventing or treating a TGFβ

-related disease, comprising the TGFβ

inhibitor according to claim 1.

7. The agent for preventing or treating a TGFβ

-related disease according to claim 6, the agent affecting an immune system cell to inhibit a reaction between TGFβ and

a receptor of the TGFβ

in the immune system cell.

8. The agent for preventing or treating a TGFβ

-related disease according to claim 6, reduce adverse reaction otherwise caused by inhibition of TGF by not completely inhibiting a reaction between TGFβ and

a receptor of the TGFβ

.

9. The agent for preventing or treating a TGFβ

-related disease according to claim 6, the agent inhibiting a reaction between TGFβ and

a receptor of the TGFβ

concentration-dependently at a concentration corresponding to an active dose of 50 nM or more, and not completely inhibiting the reaction between the TGFβ and

the receptor even at a high concentration of 375 nM or more.

10. The agent for preventing or treating a TGFβ

-related disease according to claim 6, wherein the TGFβ

-related disease is cancer, and the agent activates anti-tumor immunity.

11. The agent for preventing or treating a TGFβ

-related disease according to claim 10, wherein the agent releases immunosuppression which mediated by a regulatory T cell induced by TGFβ

secreted from a cancer cell, and the agent restores and activates attack of an immune cell against a cancer cell.